Cargando…

Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study

INTRODUCTION: The availability of targeted therapies has transformed the management of advanced NSCLC; however, most patients do not undergo guideline-recommended tumor genotyping. The impact of plasma-based next-generation sequencing (NGS) performed simultaneously with diagnostic biopsy in suspecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Jeffrey C., Aggarwal, Charu, Wong, Janeline, Nimgaonkar, Vivek, Hwang, Wei-Ting, Andronov, Michelle, Dibardino, David M., Hutchinson, Christoph T., Ma, Kevin C., Lanfranco, Anthony, Moon, Edmund, Haas, Andrew R., Singh, Aditi P., Ciunci, Christine A., Marmarelis, Melina, D’Avella, Christopher, Cohen, Justine V., Bauml, Joshua M., Cohen, Roger B., Langer, Corey J., Vachani, Anil, Carpenter, Erica L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980884/
https://www.ncbi.nlm.nih.gov/pubmed/35392653
http://dx.doi.org/10.1016/j.jtocrr.2022.100301
_version_ 1784681490259378176
author Thompson, Jeffrey C.
Aggarwal, Charu
Wong, Janeline
Nimgaonkar, Vivek
Hwang, Wei-Ting
Andronov, Michelle
Dibardino, David M.
Hutchinson, Christoph T.
Ma, Kevin C.
Lanfranco, Anthony
Moon, Edmund
Haas, Andrew R.
Singh, Aditi P.
Ciunci, Christine A.
Marmarelis, Melina
D’Avella, Christopher
Cohen, Justine V.
Bauml, Joshua M.
Cohen, Roger B.
Langer, Corey J.
Vachani, Anil
Carpenter, Erica L.
author_facet Thompson, Jeffrey C.
Aggarwal, Charu
Wong, Janeline
Nimgaonkar, Vivek
Hwang, Wei-Ting
Andronov, Michelle
Dibardino, David M.
Hutchinson, Christoph T.
Ma, Kevin C.
Lanfranco, Anthony
Moon, Edmund
Haas, Andrew R.
Singh, Aditi P.
Ciunci, Christine A.
Marmarelis, Melina
D’Avella, Christopher
Cohen, Justine V.
Bauml, Joshua M.
Cohen, Roger B.
Langer, Corey J.
Vachani, Anil
Carpenter, Erica L.
author_sort Thompson, Jeffrey C.
collection PubMed
description INTRODUCTION: The availability of targeted therapies has transformed the management of advanced NSCLC; however, most patients do not undergo guideline-recommended tumor genotyping. The impact of plasma-based next-generation sequencing (NGS) performed simultaneously with diagnostic biopsy in suspected advanced NSCLC has largely been unexplored. METHODS: We performed a prospective cohort study of patients with suspected advanced lung cancer on the basis of cross-sectional imaging results. Blood from the time of biopsy was sequenced using a commercially available 74-gene panel. The primary outcome measure was time to first-line systemic treatment compared with a retrospective cohort of consecutive patients with advanced NSCLC with reflex tissue NGS. RESULTS: We analyzed the NGS results from 110 patients with newly diagnosed advanced NSCLC: cohorts 1 and 2 included 55 patients each and were well balanced regarding baseline demographics. In cohort 1, plasma NGS identified therapeutically informative driver mutations in 32 patients (58%) (13 KRAS [five KRAS G12C], 13 EGFR, two ERRB2, two MET, one BRAF, one RET). The NGS results were available before the first oncology visit in 85% of cohort 1 versus 9% in cohort 2 (p < 0.0001), with more cohort 1 patients receiving a guideline-concordant treatment recommendation at this visit (74% versus 46%, p = 0.005). Time-to-treatment was significantly shorter in cohort 1 compared with cohort 2 (12 versus 20 d, p = 0.003), with a shorter time-to-treatment in patients with specific driver mutations (10 versus 19 d, p = 0.001). CONCLUSIONS: Plasma-based NGS performed at the time of diagnostic biopsy in patients with suspected advanced NSCLC is associated with decreased time-to-treatment compared with usual care.
format Online
Article
Text
id pubmed-8980884
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-89808842022-04-06 Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study Thompson, Jeffrey C. Aggarwal, Charu Wong, Janeline Nimgaonkar, Vivek Hwang, Wei-Ting Andronov, Michelle Dibardino, David M. Hutchinson, Christoph T. Ma, Kevin C. Lanfranco, Anthony Moon, Edmund Haas, Andrew R. Singh, Aditi P. Ciunci, Christine A. Marmarelis, Melina D’Avella, Christopher Cohen, Justine V. Bauml, Joshua M. Cohen, Roger B. Langer, Corey J. Vachani, Anil Carpenter, Erica L. JTO Clin Res Rep Brief Report INTRODUCTION: The availability of targeted therapies has transformed the management of advanced NSCLC; however, most patients do not undergo guideline-recommended tumor genotyping. The impact of plasma-based next-generation sequencing (NGS) performed simultaneously with diagnostic biopsy in suspected advanced NSCLC has largely been unexplored. METHODS: We performed a prospective cohort study of patients with suspected advanced lung cancer on the basis of cross-sectional imaging results. Blood from the time of biopsy was sequenced using a commercially available 74-gene panel. The primary outcome measure was time to first-line systemic treatment compared with a retrospective cohort of consecutive patients with advanced NSCLC with reflex tissue NGS. RESULTS: We analyzed the NGS results from 110 patients with newly diagnosed advanced NSCLC: cohorts 1 and 2 included 55 patients each and were well balanced regarding baseline demographics. In cohort 1, plasma NGS identified therapeutically informative driver mutations in 32 patients (58%) (13 KRAS [five KRAS G12C], 13 EGFR, two ERRB2, two MET, one BRAF, one RET). The NGS results were available before the first oncology visit in 85% of cohort 1 versus 9% in cohort 2 (p < 0.0001), with more cohort 1 patients receiving a guideline-concordant treatment recommendation at this visit (74% versus 46%, p = 0.005). Time-to-treatment was significantly shorter in cohort 1 compared with cohort 2 (12 versus 20 d, p = 0.003), with a shorter time-to-treatment in patients with specific driver mutations (10 versus 19 d, p = 0.001). CONCLUSIONS: Plasma-based NGS performed at the time of diagnostic biopsy in patients with suspected advanced NSCLC is associated with decreased time-to-treatment compared with usual care. Elsevier 2022-03-08 /pmc/articles/PMC8980884/ /pubmed/35392653 http://dx.doi.org/10.1016/j.jtocrr.2022.100301 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Thompson, Jeffrey C.
Aggarwal, Charu
Wong, Janeline
Nimgaonkar, Vivek
Hwang, Wei-Ting
Andronov, Michelle
Dibardino, David M.
Hutchinson, Christoph T.
Ma, Kevin C.
Lanfranco, Anthony
Moon, Edmund
Haas, Andrew R.
Singh, Aditi P.
Ciunci, Christine A.
Marmarelis, Melina
D’Avella, Christopher
Cohen, Justine V.
Bauml, Joshua M.
Cohen, Roger B.
Langer, Corey J.
Vachani, Anil
Carpenter, Erica L.
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study
title Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study
title_full Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study
title_fullStr Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study
title_full_unstemmed Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study
title_short Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study
title_sort plasma genotyping at the time of diagnostic tissue biopsy decreases time-to-treatment in patients with advanced nsclc—results from a prospective pilot study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980884/
https://www.ncbi.nlm.nih.gov/pubmed/35392653
http://dx.doi.org/10.1016/j.jtocrr.2022.100301
work_keys_str_mv AT thompsonjeffreyc plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT aggarwalcharu plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT wongjaneline plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT nimgaonkarvivek plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT hwangweiting plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT andronovmichelle plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT dibardinodavidm plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT hutchinsonchristopht plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT makevinc plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT lanfrancoanthony plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT moonedmund plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT haasandrewr plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT singhaditip plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT ciuncichristinea plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT marmarelismelina plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT davellachristopher plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT cohenjustinev plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT baumljoshuam plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT cohenrogerb plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT langercoreyj plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT vachanianil plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy
AT carpentererical plasmagenotypingatthetimeofdiagnostictissuebiopsydecreasestimetotreatmentinpatientswithadvancednsclcresultsfromaprospectivepilotstudy